- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis shows that the financial resources of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are highly valuable as these help in investing into external opportunities that arise. These also help Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B in combating external threats.
- According to the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis shows that Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B's products.
- According to the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. These patents also provide Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B with licensing revenue when it licenses these patents out to other manufacturers.
- The Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis shows that Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis shows that the research and development at Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are found to be rare according to the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B and inhibit competitive advantage. This means that the local food products result in competitive parity for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. As this resource is valuable, Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B can still make use of this resource.
- The employees of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are a rare resource as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are a rare resource as identified by the Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B to use them without interference from the competition.
- The distribution network of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B is a rare resource as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are costly to imitate as identified by the Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are also not costly to imitate as identified by the Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are very difficult to imitate as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B is also very costly to imitate by competition as identified by the Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. This has been developed over the years gradually by Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are organised to capture value as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B.
- The Patents of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B are not well organised as identified by the Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B starts selling patented products before the patents expire.
- The distribution network of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B is organised as identified by the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B. Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B.
From the VRIO Analysis of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Wyeth Pharmaceuticals in 2009 Transformation at the Site Level B is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Jenna Spencer
5.0
My elder brother had been using this corporation since 2012 so I drop the order now freely for any assignment. Highly recommended!
Kristen Jay
5.0
Wanna recommend this company for a difficult situation when you don’t have enough time to write the project and also lack sufficient money. Place order and have gratitude for me.
Yang Bojing
5.0
Just an awesome experience and these guys are helpful for correcting the paper with respect to an error. Thank you!
Amelia Strewart
5.0
Everything was perfect and it's a pretty good service. This customer service is up to leveled and great. Highly recommended!
Next Articles
- The Flaxil Label (C): Debrief And Endnotes Vrio Analysis
- Shar Matin (A) Vrio Analysis
- RU 486 (A) Vrio Analysis
- Brush With AIDS (B) Vrio Analysis
- Merck Global Health Initiatives (A) Vrio Analysis
- Hans Fritz At Novartis Thailand (A): The First Month Vrio Analysis
- GLAXOSMITHKLINE AND AIDS DRUGS IN SOUTH AFRICA (C): THE FIGHT GOES ON Vrio Analysis
- Merck & Company: Product KL 798 Vrio Analysis
- The Paradox Of Pharmaceutical CSR: The Sincerity Nexus Vrio Analysis
- The Flaxil Label (A) Vrio Analysis
Previous Articles
- GLAXOSMITHKLINE AND AIDS DRUGS IN SOUTH AFRICA (D): US DEVELOPMENTS Vrio Analysis
- Sms For Life (C): Sustaining The Initiative And Leveraging Its Social And Business Value For Novartis Vrio Analysis
- Jan Eriksson At Novartis Indonesia (B) Vrio Analysis
- Rx Depot: Importing Drugs From Canada Vrio Analysis
- Hans Fritz At Novartis Thailand (B): The First Six Months Vrio Analysis
- Sms For Life (A): A Public Private Collaboration To Prevent Stock Outs Of Life Saving Marlaria Drugs In Africa Vrio Analysis
- Antegren: A Beacon Of Hope (D) Vrio Analysis
- Wyeth Pharmaceuticals In 2009: Transformation At The Site Level Vrio Analysis
- Kevin Simpson At Haemonetics, Video Vrio Analysis
- Hans Fritz At Novartis Thailand (D): The First 18 Months Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!